Skip to main content
Axel Markets

The Indian stock screener that knows when smart money is moving.

Everything screener.in does — fundamentals filtering, custom queries, sector slicing — plus three things they can't: 3-lens verdicts on every result, instead of absolute P/E thresholds, and an AI that understands “debt-free midcap pharma compounders” the way you mean it. Ask in plain English below, or refine with the form. Free, no signup.

CURATED PRESETS · ONE-CLICK SCREENS
Community screens →

Hand-tuned screens with live results. Each preset links to a dedicated page with commentary, refinement, and Axel narration.

High ROCE · low debt →
Indian companies delivering ROCE above 20% with debt-to-equity below 0.5 · quality compounders that make money without leverage. Filtered live from NSE/BSE XBRL filings. Free, no signup.
Value large-caps →
Large-cap Indian stocks (market cap > ₹50,000 Cr) trading under P/E 15 with ROE above 15% · the classic value-at-scale screen. Data from NSE/BSE public filings, refreshed daily.
Debt-free growth →
Indian stocks with debt-to-equity below 0.1 and revenue YoY growth above 20% · growth compounders that fund expansion from internal accruals, not borrowings. Live from XBRL filings.
Small-cap growth →
Small-cap Indian companies (₹500–5,000 Cr market cap) growing revenue above 25% YoY with positive profit growth. High-risk, high-potential universe · filter before research.
High ROE compounders →
Indian stocks with ROE above 18% and positive revenue growth · the Buffett-style quality-compounder screen. Applied to the full NSE/BSE universe, refreshed daily.
Mid-cap value →
Mid-cap Indian stocks (₹5,000–50,000 Cr) trading below P/E 20 with ROE above 15% · the sweet-spot universe where large-cap stability meets small-cap growth without either's extremes.
Consistent profit growers →
Indian stocks with profit YoY growth above 25% and revenue growth above 15% · operational-leverage compounders where the bottom line grows faster than the top.
Affordable quality →
Classic GARP (growth at reasonable price) screen for Indian equities · ROE above 15%, P/E under 20, debt-to-equity below 0.75. Finds the unsexy-but-solid that neither value nor growth camps fight over.
Low P/B · high ROE →
Indian stocks trading below 3× book value with ROE above 18% · the modern P/B-quality intersection that filters out asset-heavy value traps. Refreshed daily.
Pledge-free quality →
Indian stocks where promoters have NOT pledged their shares (pledged % below 5%) and the business has ROE above 15%. Promoter pledge is a flashing red flag for governance + leverage; this screen sidesteps it.
Convergence + quality →
The intersection of our 3-lens Master Convergence framework (3-of-3 bullish) and Piotroski quality (8+/9). Our highest-conviction band by independent academic framework — quality and convergence agree.
Smart money · large-caps →
Large-cap Indian stocks (₹50,000 Cr+) with our Smart Money score above 70 · stocks where institutional accumulation is ongoing across SEBI insider, block-deal, and shareholding-pattern feeds.
Big revenue · clean balance →
Indian companies with TTM revenue over ₹5,000 Cr AND debt-to-equity below 0.5 · the operationally-significant + balance-sheet-clean intersection. For investors who want scale without leverage risk.
Sector-cheap quality →
Stocks scoring 65+ on our sector-relative valuation lens AND 70+ on Piotroski quality · the cleanest 'cheap relative to peers + actually well-run' intersection. Refreshed daily.

How this screener works

Every fundamental number below comes from public NSE / BSE XBRL quarterly + annual filings. We parse IND-AS taxonomy filings weekly, normalise to our Supabase schema, and compute valuation ratios daily against the live close price. Same source Screener.in uses; we're just presenting it alongside Axel and the 100+ other tools on this platform.

Current coverage:NIFTY 50 + Next 50 constituents, growing weekly as our ingestion pipeline expands to the full ~2,000 listed companies. If a stock you searched isn't here yet, it will appear after the next cron cycle (Sundays 02:00 IST).

Data freshness: ratios recompute daily at market close. Financials update within 48 hours of a quarterly filing.

ASK AXEL

Chat-first screening beats filter-form screening

Describe what you want in one line. Axel translates to precise filters, runs the screener, explains its interpretation so you can refine. Research framing only. Not a buy/sell recommendation.

Ask Axel free

Research tool · not investment advice.

Axel Markets is an information + analytics product. We are not a SEBI-registered Research Analyst (RA) or Investment Adviser (IA). Nothing on this page is a buy, sell, or hold recommendation. Past performance is not indicative of future returns. Verify all data against the authoritative source (NSE, BSE, AMFI, SEBI, company RHP / factsheet) before acting. Screener results are a data-driven filter of publicly-disclosed financials from NSE + BSE XBRL filings. Not investment advice, not a buy/sell recommendation. Filters reflect the metrics you've specified; they do not encapsulate company-specific risks, management quality, sector cyclicality, or forward prospects. Always combine screener output with qualitative analysis before making any investment decision.